Aktis Oncology, Inc. (AKTS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$27.05+1.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AKTS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -24.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 65.9% |
Growth built into the price is above our model estimate.
The price assumes 90.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AKTS — earnings in line
Dated 2026-08-13
of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Why it matters: Preliminary data will show how well AKY-2519 works in treating mCRPC. Positive results could boost confidence in the drug's potential.
Supportive ifEarly data shows a big drop in tumor size or growth in mCRPC patients.
Worry ifData shows no big change in tumor size or growth in mCRPC patients.
Why it matters: Starting this trial shows Aktis is expanding its research and could lead to new treatment options for more patients.
Supportive ifThe company announces the start of the Phase 1b basket trial for AKY-2519.
Worry ifThe trial is delayed or not initiated as planned in the second half of 2026.
Why it matters: This data will show how well AKY-2519 works in treating mCRPC. Positive results could boost confidence in the drug's potential.
Supportive ifEarly data shows that AKY-2519 works well for treating advanced prostate cancer.
Worry ifData shows low effectiveness and safety issues in the mCRPC patient group.
Why it matters: Starting the Phase 1b trial is key for Aktis's growth in oncology. It shows progress in their drug development.
Supportive ifA press release confirming the initiation of the Phase 1b basket trial in the second half of 2026.
Worry ifNo announcement of the Phase 1b trial initiation by the end of 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$271 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $594 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,219 loss on $10,000 · 32.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Getting the GMP facility running is key. It helps with clinical supply and future trials.
Supportive ifAn announcement will confirm the GMP facility is running in the second half of 2026.
Worry ifNo news on the GMP facility's status by the end of 2026.
Why it matters: Cash updates will show financial health. They indicate the ability to fund ongoing trials.
Worry ifCash position stays the same or goes up after the GMP facility opens.
Less concerning ifCash position falls a lot after the GMP facility opens.
Why it matters: This presentation will explain how AKY-2519 works in the body. Good data may attract investors.
Supportive ifThe ASCO presentation shows good data on how AKY-2519 spreads and its dosage.
Worry ifThe data raises safety issues or shows that it does not work well.
Why it matters: Starting this trial would show progress in expanding the company's oncology pipeline. It is a key step in their growth strategy.
Supportive ifThe Phase 1b trial for AKY-2519 in B7-H3 tumors begins as planned in the second half of 2026.
Worry ifThe trial does not start as planned or is delayed beyond 2026.
Why it matters: Data from this trial could validate the company's approach and attract further investment. It is a critical milestone.
Supportive ifPreliminary data from the ongoing Phase 1b trial of AKY-1189 is reported in the first quarter of 2027.
Worry ifData is not reported as expected or shows poor results.
Why it matters: A GMP facility is important for clinical supply. It can help the company make more products.
Supportive ifThe GMP facility will start operating in the second half of 2026.
Worry ifThe facility may be delayed or may not start as planned.
Why it matters: Growth in collaboration revenue shows strong partnerships. It can help the company during clinical trials.
Supportive ifCollaboration revenue is expected to grow. It may reach over $3.4 million next quarter.
Worry ifCollaboration revenue may drop or stay the same at $3.4 million.